Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease

Table 1 Demographics of subjects at baseline

Characteristics	CN (n = 52)	sMCI (n = 22)	pMCI (n = 47)	AD (n = 18)
Age (years)	76.2 (5.1)	76.0 (5.1)	73.1 (6.6)	74.3 (7.0)
Gender, female (%)	22 (42.3%)	7 (31.8%)^d	14 (29.8%)^d	11 (61.1%)
Education (years)	15.7 (3.3)	16.8 (2.4)	15.9 (2.7)	15.2 (2.9)
APOE ε4, n (%)	10 (19.2%)^c,d	7 (31.8%)^c,d	28 (59.6%)^a,b	13 (72.2%)^a,b
MMSE	29.3 (1.0)^b,c,d	27.2 (1.4)^a,d	26.6 (1.6)^a,d	24.2 (2.1)^a,b,c
ADAS-cog	5.9 (2.8)^b,c,d	9.2 (3.8)^a,c,d	12.5 (4.3)^a,b,d	18.2 (6.1)^a,b,c
Aβ42 (pg/ml)	211.4 (56.2)^b,c,d	181.0 (54.7)^a,c,d	147.5 (47.8)^a,b	136.1 (27.3)^a,b
t-tau (pg/ml)	72.7 (28.5)^c,d	84.7 (54.0)^d	107.8 (49.3)^a,d	153.2 (78.7)^a,b,c
t-tau/Aβ42	0.399 (0.283)^c,d	0.553 (0.492)^c,d	0.820 (0.501)^a,b,d	1.138 (0.569)^a,b,c
p-tau (pg/ml)	24.6 (10.4)^c,d	28.1 (15.7)^c,d	39.5 (16.5)^a,b	45.8 (16.4)^a,b
p-tau/Aβ42	0.135 (0.095)^c,d	0.184 (0.147) ^c,d	0.303 (0.162)^a,b	0.350 (0.145)^a,b
Follow-up (years)	7.5 (2.6)^b,c,d	4.8 (2.5)^a,d	5.7 (2.6)^a,d	2.6 (0.7)^a,b,c

Values are shown as mean ± standard deviation unless otherwise indicated
p values indicate the values assessed with analyses of variance for each variable except gender and APOE ε4, where a contingency chi-square was performed. Post-hoc analysis provided significant differences between groups: ^a versus CN; ^b versus sMCI; ^c versus pMCI; ^d versus AD.
Aβ amyloid-β, AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale cognitive subscale, APOE apolipoprotein E, CN cognitively normal, MMSE Mini-Mental State Examination, pMCI progressive mild cognitive impairment, p-tau phosphorylated tau, sMCI stable mild cognitive impairment, t-tau total tau

ISSN: 1758-9193